Vifor Fresenius Medical Care Renal Pharma - partner of choice for renal pharmaceuticals and innovative, patient-centric solutions
Vifor Fresenius Medical Care Renal Pharma is a rapidly-growing international company that focuses on nephrology. We combine the strengths of our two shareholders: Vifor Pharma, a pharmaceutical company specialising in the treatment of iron deficiency, and Fresenius Medical Care, one of the world’s leading providers of expert patient care and dialysis services.
www.viforpharma.com
www.shptchallenges.com
www.viforpharma.com Vifor Fresenius Medical Care Renal Pharma is a rapidly-growing international company that focuses on nephrology. We combine the strengths of our two shareholders: Vifor Pharma, a pharmaceutical company specialising in the treatment of iron deficiency, and Fresenius Medical Care, one of the world’s leading providers of expert patient care and dialysis services.
www.viforpharma.com
www.shptchallenges.com
AMOUNT: 33.000 Euros
Vifor Fresenius Medical Care Renal Pharma supports the Nephro Update Europe 2020 as a Gold Partner.
Vifor Fresenius Medical Care Renal Pharma supports the Nephro Update Europe 2020 as a Gold Partner.
Medtronic is the global leader medical technology, alleviating pain, restoring health an extending life for millions of people around the world. With deep roots in the treatment of heart disease, Medtronic now provides a wide range of products and therapies - every three seconds, another life is improved by a Medtronic product or therapy.
www.medtronic.com AMOUNT: 17.500 Euros
Medtronic supports the Nephro Update Europe 2020 as Silver Partner.
Medtronic supports the Nephro Update Europe 2020 as Silver Partner.
In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance in the field of diabetes that centres on three pipeline compounds representing several of the largest treatment classes. This Alliance leverages the companies’ strengths as two of the world’s leading pharmaceutical companies, combining Boehringer Ingelheim’s solid track record of research-driven innovation and Lilly’s innovative research, experience and pioneering history in diabetes.
www.boehringer-ingelheim.com AMOUNT: 10.000 Euros
Boehringer Ingelheim & Eli Lilly Alliance supports the Nephro Update Europe 2020 as Partner.
Boehringer Ingelheim & Eli Lilly Alliance supports the Nephro Update Europe 2020 as Partner.
Kyowa Kirin International plc is owned by Kyowa Kirin Co., Ltd. of Japan. Founded in 1949, Kyowa Kirin has a successful track record in Japan and is now expanding globally. Our highly successful product portfolio, enviable pipeline and active Business Development group provides a wealth of products in the therapeutic areas of Oncology, CNS and Nephrology. With three key anti-body therapies in late stage development Kyowa Kirin is setting the scene for transformative growth.
www.international.kyowa-kirin.com AMOUNT: 10.000 Euros
Kyowa Kirin International supports the Nephro Update Europe 2020 as Partner.
Kyowa Kirin International supports the Nephro Update Europe 2020 as Partner.
AstraZeneca is a global, science-led biopharmaceutical business and its innovative medicines are used by millions of patients worldwide. Driven by innovative science and entrepreneurial culture, AstraZeneca is focused on the delivery of life-changing medicines that are fuelling growth and contributing value to patients and society.
https://www.astrazeneca.com/ AMOUNT: 3.000 Euros
AstraZeneca BV supports the Nephro Update Europe 2020 as Partner.
AstraZeneca BV supports the Nephro Update Europe 2020 as Partner.
